Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T08:57:23.673Z Has data issue: false hasContentIssue false
  • English
  • Français

HEPARIN IN HUMAN PLACENTAL DEVELOPMENT AND THE PREVENTION OF PLACENTAL COMPLICATIONS OF PREGNANCY

Part of: Bespoke shallow archive Weizmann

Published online by Cambridge University Press:  18 August 2010

SASCHA DREWLO ,
MELISSA WALKER ,
ANNE MCLEOD ,
JODIE DODD  and
JOHN KINGDOM
SASCHA DREWLO
Affiliation:
Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Canada Department of Obstetrics & Gynaecology, University of Toronto, Canada
MELISSA WALKER
Affiliation:
Department of Obstetrics & Gynaecology at Mount Sinai Hospital, Canada
ANNE MCLEOD
Affiliation:
Department of Medicine, Sunnybrook Hospital, Canada
JODIE DODD
Affiliation:
Department of Obstetrics & Gynaecology, University of Adelaide, Australia
JOHN KINGDOM*
Affiliation:
Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Canada Department of Obstetrics & Gynaecology at Mount Sinai Hospital, Canada Department of Obstetrics & Gynaecology, University of Toronto, Canada
*
Correspondence to: Dr J Kingdom, Department of Obstetrics & Gynaecology, Room 3265, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, CanadaM5G 1 × 5. Email: jkingdom@mtsinai.on.ca
Get access Rights & Permissions [Opens in a new window]

Extract

The development of effective anticoagulant drugs available for use in pregnancy has resulted in dramatic improvements for a number of potentially life-threatening conditions. These include the treatment and prevention of venous thromboembolism and the thrombotic complications of antiphospholipid antibody syndrome, as well as the management of pregnant women with mechanical heart valves. The most commonly used class of drug includes heparin, a highly-charged macro-molecule that does not cross the placenta, in contrast to the potentially teratogenic and fetotoxic oral drug warfarin. This review will focus on our current lack of understanding of the wider actions of heparin and examines the possibility that large numbers of pregnant women are presently being treated inappropriately with heparin.

Type
Research Article
Information
Fetal and Maternal Medicine Review , Volume 21 , Issue 3 , August 2010 , pp. 185 - 203
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1Blanco-Molina, A, Trujillo-Santos, J, Criado, J, Lopez, L, Lecumberri, R, Gutierrez, R, et al. . Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost 2007; 97: 186–90.Google Scholar
2Hanprasertpong, T, Hanprasertpong, J, Riabroi, K. Cerebral venous sinus thrombosis in early pregnancy: an unusual presentation of primary antiphospholipid syndrome. J Obstet Gynaecol Res 2009; 35: 1125–128.CrossRefGoogle ScholarPubMed
3Yinon, Y, Siu, SC, Warshafsky, C, Maxwell, C, McLeod, A, Colman, JM, et al. . Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol 2009; 104: 1259–263.Google Scholar
4Mehndiratta, S, Suneja, A, Gupta, B, Bhatt, S. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet 2010 Jan 29. (epub ahead of print)Google Scholar
5Petitou, M, Nancy-Portebois, V, Dubreucq, G, Motte, V, Meuleman, D, de Kort, M, et al. . From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804–10.Google Scholar
6Greer, I, Hunt, BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005; 128: 593–601.CrossRefGoogle ScholarPubMed
7Warkentin, TE, Greinacher, A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 311S–37S.Google Scholar
8Carlin, AJ, Farquharson, RG, Quenby, SM, Topping, J, Fraser, WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 2004; 19: 1211–214.CrossRefGoogle ScholarPubMed
9Backos, M, Rai, R, Thomas, E, Murphy, M, Dore, C, Regan, L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14: 2876–880.Google Scholar
10Rodger, MA, Kahn, SR, Cranney, A, Hodsman, A, Kovacs, MJ, Clement, AM, et al. . Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007; 5: 1600–606.CrossRefGoogle Scholar
11Ekman-Ordeberg, G, Akerud, A, Dubicke, A, Malmstrom, A, Hellgren, M. Does low molecular weight heparin shorten term labor? Acta Obstet Gynecol Scand 2010; 89: 147–50.CrossRefGoogle ScholarPubMed
12Linhardt, RJ, Gunay, NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25 Suppl 3: 5–16.Google Scholar
13Sasisekharan, R, Venkataraman, G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol. 2000; 4: 626–31.CrossRefGoogle ScholarPubMed
14Hirsh, J, Warkentin, TE, Shaughnessy, SG, Anand, SS, Halperin, JL, Raschke, R, et al. . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl): 64S–94S.Google Scholar
15Collignon, F, Frydman, A, Caplain, H, Ozoux, ML, Le Roux, Y, Bouthier, J, et al. . Comparison of the pharmacokinetic profiles of three low molecular mass heparins–dalteparin, enoxaparin and nadroparin–administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630–40.Google Scholar
16Horlocker, TT, Wedel, DJ, Rowlingson, JC, Enneking, FK, Kopp, SL, Benzon, HT, et al. . Regional anaesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64–101.CrossRefGoogle ScholarPubMed
17Conti, S, Guercini, F, Iorio, A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb. 2003; 33: 197–201.CrossRefGoogle Scholar
18Lazo-Langner, A, Goss, GD, Spaans, JN, Rodger, MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729–37.Google Scholar
19Nishioka, J, Goodin, S. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract 2007; 13: 85–97.Google Scholar
20Casu, B, Vlodavsky, I, Sanderson, RD. Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 2008; 36: 195–203.CrossRefGoogle ScholarPubMed
21Mohammadi, M, Olsen, SK, Ibrahimi, OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16: 107–37.Google Scholar
22Ilan, N, Elkin, M, Vlodavsky, I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018–39.Google Scholar
23Azem, F, Many, A, Ben Ami, I, Yovel, I, Amit, A, Lessing, JB, et al. . Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19: 368–70.Google Scholar
24Qublan, HS, Eid, SS, Ababneh, HA, Amarin, ZO, Smadi, AZ, Al-Khafaji, FF, et al. . Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod 2006; 21: 2694–698.Google Scholar
25Kaider, BD, Price, DE, Roussev, RG, Coulam, CB. Antiphospholipid antibody prevalence in patients with IVF failure. Am J Reprod Immunol 1996; 35: 388–93.Google Scholar
26Geva, E, Yaron, Y, Lessing, JB, Yovel, I, Vardinon, N, Burke, M, et al. . Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization. Fertil Steril 1994; 62: 802–806.Google Scholar
27Birkenfeld, A, Mukaida, T, Minichiello, L, Jackson, M, Kase, NG, Yemini, M. Incidence of autoimmune antibodies in failed embryo transfer cycles. Am J Reprod Immunol 1994; 31: 65–68.CrossRefGoogle ScholarPubMed
28Coulam, CB, Jeyendran, RS, Fishel, LA, Roussev, R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006; 12: 322–27.CrossRefGoogle ScholarPubMed
29Denis, AL, Guido, M, Adler, RD, Bergh, PA, Brenner, C, Scott, RT Jr.Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Fertil Steril 1997; 67: 1084–90.CrossRefGoogle ScholarPubMed
30Simur, A, Ozdemir, S, Acar, H, Colakoglu, MC, Gorkemli, H, Balci, O, et al. . Repeated in vitro fertilization failure and its relation with thrombophilia. Gynecol Obstet Invest 2009; 67: 109–12.Google Scholar
31Martinelli, I, Taioli, E, Ragni, G, Levi-Setti, P, Passamonti, SM, Battaglioli, T, et al. . Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88: 789–93.Google Scholar
32Nelson, SM, Greer, IA. The potential role of heparin in assisted conception. Hum Reprod Update 2008; 14: 623–45.CrossRefGoogle ScholarPubMed
33Chamley, LW, Duncalf, AM, Mitchell, MD, Johnson, PM. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352: 1037–38.Google Scholar
34Di Simone, N, Meroni, PL, de Papa, N, Raschi, E, Caliandro, D, De Carolis, CS, et al. . Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43: 140–50.3.0.CO;2-P>CrossRefGoogle ScholarPubMed
35Girardi, G, Redecha, P, Salmon, JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–226.Google Scholar
36Qublan, H, Amarin, Z, Dabbas, M, Farraj, AE, Beni-Merei, Z, Al-Akash, H, et al. . Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil 2008; 11: 246–53.CrossRefGoogle ScholarPubMed
37Urman, B, Ata, B, Yakin, K, Alatas, C, Aksoy, S, Mercan, R, et al. . Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod 2009; 24: 1640–647.Google Scholar
38Horne, AW, Alexander, CI. Recurrent miscarriage. J Fam Plann Reprod Health Care. 2005; 31: 103–107.Google Scholar
39ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynecol Obstet 2002; 78: 179–90.Google Scholar
40Kaandorp, S, Di Nisio, M, Goddijn, M, Middeldorp, S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2009: CD004734.Google Scholar
41Rey, E, Kahn, SR, David, M, Shrier, I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901–908.Google Scholar
42Levine, JS, Branch, DW, Rauch, J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752–63.CrossRefGoogle ScholarPubMed
43Empson, M, Lassere, M, Craig, J, Scott, J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005: CD002859.Google Scholar
44Laskin, CA, Spitzer, KA, Clark, CA, Crowther, MR, Ginsberg, JS, Hawker, GA, et al. . Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279–87.Google Scholar
45Dolitzky, M, Inbal, A, Segal, Y, Weiss, A, Brenner, B, Carp, H. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86: 362–66.Google Scholar
46Kaandorp, S, Goddijn, M, Van Der Post, JA, Hutten, BA, Verhoeve, HR, Hamulyak, K, et al. . Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study). Blood 2009; 114: Abstract 488.Google Scholar
47Hull, MG, North, K, Taylor, H, Farrow, A, Ford, WC. Delayed conception and active and passive smoking. The Avon Longitudinal Study of Pregnancy and Childhood Study Team. Fertil Steril 2000; 74: 725–33.Google Scholar
48Berthiller, J, Sasco, AJ. [Smoking (active or passive) in relation to fertility, medically assisted procreation and pregnancy]. J Gynecol Obstet Biol Reprod 2005; 34 Spec No 1: 3S47–54.Google Scholar
49Eggert, J, Theobald, H, Engfeldt, P. Effects of alcohol consumption on female fertility during an 18-year period. Fertil Steril 2004; 81: 379–83.Google Scholar
50Clark, P, Walker, ID, Langhorne, P, Crichton, L, Thomson, A, Greaves, M, et al. . SPIN: the Scottish Pregnancy Intervention Study: a multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood 2010; 115: 4162–167.CrossRefGoogle Scholar
51Ball, E, Robson, SC, Ayis, S, Lyall, F, Bulmer, JN. Early embryonic demise: no evidence of abnormal spiral artery transformation or trophoblast invasion. J Pathol 2006; 208: 528–34.CrossRefGoogle ScholarPubMed
52Smith, GC, Wood, AM. Recurrent first trimester spontaneous losses are associated with a family history of ischemic heart disease. Reprod Sci [Abstract]. 2010; 17: 288A.Google Scholar
53Ferrazzi, E, Bulfamante, G, Mezzopane, R, Barbera, A, Ghidini, A, Pardi, G. Uterine Doppler velocimetry and placental hypoxic-ischaemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta 1999; 20: 389–94.CrossRefGoogle ScholarPubMed
54Viero, S, Chaddha, V, Alkazaleh, F, Simchen, MJ, Malik, A, Kelly, E, et al. . Prognostic value of placental ultrasound in pregnancies complicated by absent end-diastolic flow velocity in the umbilical arteries. Placenta 2004; 25: 735–41.Google Scholar
55Toal, M, Keating, S, Machin, G, Dodd, J, Adamson, SL, Windrim, RC, et al. . Determinants of adverse perinatal outcome in high-risk women with abnormal uterine artery Doppler images. Am J Obstet Gynecol 2008; 198: 330e1–7.Google Scholar
56Thrombophilia in Pregnancy Prophylaxis study (TIPPS). <http://wwwohrica/programs/clinical_epidemiology/Thrombosis_Group/studies/TIPPSasp>. 2009..+2009.>Google Scholar
57Abou-Nassar, K, Kovacs, MJ, Kahn, SR, Wells, P, Doucette, S, Ramsay, T, et al. . The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163–71.Google Scholar
58Dodd, M, Windrim, , Kingdom, J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010; 6: CD006780.Google Scholar
59North, RA, Ferrier, C, Gamble, G, Fairley, KF, Kincaid-Smith, P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aust N Z J Obstet Gynaecol 1995; 35: 357–62.Google Scholar
60Mello, G, Parretti, E, Fatini, C, Riviello, C, Gensini, F, Marchionni, M, et al. . Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86–91.CrossRefGoogle ScholarPubMed
61Yu, YH, Shen, LY, Zhong, M, Zhang, Y, Su, GD, Gao, YF, et al. . Effect of heparin on fetal growth restriction. Zhonghua Fu Chan Ke Za Zhi 2004; 39: 793–96.Google Scholar
62Rey, E, Garneau, P, David, M, Gauthier, R, Leduc, L, Michon, N, et al. . Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58–64.Google Scholar
63Toal, M, Chaddha, V, Windrim, R, Kingdom, J. Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin. J Obstet Gynaecol Can 2008; 30: 198–206.Google Scholar
64Proctor, LK, Toal, M, Keating, S, Chitayat, D, Okun, N, Windrim, RC, et al. . Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2009; 34: 274–82.Google Scholar
65Toal, M, Chan, C, Fallah, S, Alkazaleh, F, Chaddha, V, Windrim, RC, et al. . Usefulness of a placental profile in high-risk pregnancies. Am J Obstet Gynecol 2007; 196: 363 e1–7.CrossRefGoogle ScholarPubMed
66Dugoff, L, Hobbins, JC, Malone, FD, Vidaver, J, Sullivan, L, Canick, JA, et al. . Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005; 106: 260–67.Google Scholar
67Pasupathy, D, Dacey, A, Cook, E, Charnock-Jones, DS, White, IR, Smith, GC. Study protocol. A prospective cohort study of unselected primiparous women: the pregnancy outcome prediction study. BMC Pregnancy Childbirth 2008; 8: 51.Google Scholar
68Kaufman, P. Vergleichend-anatomische und funktionelle Aspekte des Placenta-Baues. Funkt Biol Med 1983: 71–79.Google Scholar
69Cross, JC, Nakano, H, Natale, DR, Simmons, DG, Watson, ED. Branching morphogenesis during development of placental villi. Differentiation 2006; 74: 393–401.CrossRefGoogle ScholarPubMed
70Huppertz, B. IFPA Award in Placentology Lecture: Biology of the placental syncytiotrophoblast–myths and facts. Placenta 2010; 31 Suppl: S75–81.Google Scholar
71Aplin, JD. Developmental cell biology of human villous trophoblast: current research problems. Int J Dev Biol 2010; 54: 323–29.Google Scholar
72Burton, GJ, Woods, AW, Jauniaux, E, Kingdom, JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009; 30: 473–82.Google Scholar
73Nevo, O, Soleymanlou, N, Wu, Y, Xu, J, Kingdom, J, Many, A, et al. . Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regulatory Integrative Comp Physiol 2006; 291: R1085–93.Google Scholar
74Benirschke, K, Kaufmann, P. Pathology of the Human Placenta. 4th Edition ed. New York: Springer-Verlag; 2006; 47–55.Google Scholar
75Baczyk, D, Drewlo, S, Proctor, L, Dunk, C, Lye, S, Kingdom, J. Glial cell missing-1 transcription factor is required for the differentiation of the human trophoblast. Cell Death Differ 2009; 16: 719–27.CrossRefGoogle ScholarPubMed
76Baczyk, D, Dunk, C, Huppertz, B, Maxwell, C, Reister, F, Giannoulias, D, et al. . Bi-potential behaviour of cytotrophoblasts in first trimester chorionic villi. Placenta 2006; 27: 367–74.CrossRefGoogle ScholarPubMed
77Facchinetti, F, Marozio, L, Frusca, T, Grandone, E, Venturini, P, Tiscia, GL, et al. . Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200: 46e1–5.Google Scholar
78Gris, JC, Lissalde-Lavigne, G, Quere, I, Dauzat, M, Mares, P. Prophylaxis and treatment of thrombophilia in pregnancy. Curr Opin Hematol 2006; 13: 376–81.Google Scholar
79Sood, R, Kalloway, S, Mast, AE, Hillard, CJ, Weiler, H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 2006; 107: 3173–80.Google Scholar
80Munoz, EM, Linhardt, RJ. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol 2004; 24: 1549–557.Google Scholar
81Drewlo, S, Levytska, K, Baczyk, D, Sobel, M, Kingdom, J. Heparin elevates sFLT-1 secretion and impairs villous trophoblast physiology in a dose-dependent manner: Implications for the prevention of severe preeclampsia? Reprod Sci 2010; 17 (3 (Supplement)): 121A.Google Scholar
82Tanaka, S, Kunath, T, Hadjantonakis, AK, Nagy, A, Rossant, J. Promotion of trophoblast stem cell proliferation by FGF4. Science 1998; 282: 2072–75.Google Scholar
83Bose, P, Black, S, Kadyrov, M, Bartz, C, Shlebak, A, Regan, L, et al. . Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004; 191: 2125–131.Google Scholar
84Haimov-Kochman, R, Friedmann, Y, Prus, D, Goldman-Wohl, DS, Greenfield, C, Anteby, EY, et al. . Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod 2002; 8: 566–73.Google Scholar
85Vlodavsky, I, Ilan, N, Nadir, Y, Brenner, B, Katz, BZ, Naggi, A, et al. . Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007; 120 Suppl 2: S112–20.Google Scholar
86Fux, L, Ilan, N, Sanderson, RD, Vlodavsky, I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009; 34: 511–19.Google Scholar
87Fox, H. Morphological changes in the human placenta following fetal death. J Obstet Gynaecol Br Commonw 1968; 75: 839–43.Google Scholar